News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2019
-
Mar 26, 2019
Chugai’s Actemra Intravenous Infusion Receives Approval for Additional Indication and Dosing for Cytokine Release Syndrome
[PDF 99KB] -
Mar 26, 2019
Anti-CD20 Monoclonal Antibody “RITUXAN®,” Approved for Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia
[PDF 77KB] -
Mar 19, 2019
Miraca and Chugai Enter into Business Partnership Agreement for “FoundationOne® CDx Cancer Genome Profile”
[PDF 141KB] -
Mar 15, 2019
Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of ROS1 Fusion-Positive Non-Small Cell Lung Cancer
[PDF 200KB] -
Mar 14, 2019
Chugai’s Hemlibra Receives Approval for Severe Hemophilia A without Factor VIII Inhibitors from the European Commission
[PDF 377KB] -
Mar 11, 2019
Galderma Presented Results from Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis at the 2019 AAD Annual Meeting Late-breaking Session
[PDF 281KB] -
Feb 13, 2019
Chugai’s Actemra, the World’s First Anti-IL-6 Receptor Antibody Created in Japan, Wins Chairman’s Award of Japan Techno-Economics Society
[PDF 93KB] -
Feb 12, 2019
Chugai Wins Second Prize in 21st NIKKEI Annual Report Awards
[PDF 142KB] -
Feb 06, 2019
Together with Roche, Chugai Joins the World Federation of Hemophilia Humanitarian Aid Program
[PDF 178KB] -
Feb 05, 2019
The 1st Japan Open Innovation Prize: Four Parties including Osaka University Win the Minister of Education, Culture, Sports, Science and Technology Award for “University-Industry Co-creation from the Basic Research Stage -Collaboration between Organizations-”
[PDF 230KB] -
Feb 04, 2019
Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A without Inhibitors
[PDF 187KB] -
Jan 31, 2019
Chugai Announces 2018 Full Year Results and Forecasts for 2019
[PDF 265KB] -
Jan 31, 2019
Chugai Announces New Mission Statement and New Mid-Term Business Plan “IBI 21,” Striving to Develop Hand in Hand with Society through Creation of Innovative Drugs and Services
[PDF 176KB] -
Jan 31, 2019
Notice of Distribution of Retained Earnings
[PDF 139KB] -
Jan 31, 2019
Organizational and Personnel Changes
[PDF 269KB] -
Jan 31, 2019
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2018
[PDF 70KB] -
Jan 30, 2019
Chugai Transfers Rights to Maruho for Oxarol® Ointment 25µg/g and Oxarol® Lotion 25µg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
[PDF 113KB] -
Jan 18, 2019
Chugai Files an Application for Expanded Use of Genomic Mutation Analysis Program “FoundationOne® CDx Cancer Genomic Profile”
-- Aiming to develop a companion diagnostic for entrectinib -- [PDF 67KB] -
Jan 10, 2019
MI Chat, a ChatBot for Healthcare Professionals, Starts Today to Respond to Inquiries about Product Information
[PDF 115KB] -
Jan 08, 2019
Completion of Transfer of Marketing and Manufacturing Rights of 13 Long-Term Listed Products from Chugai to Taiyo Pharma
[PDF 102KB]
